These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 36438489)
1. N6-methyladenosine-associated prognostic pseudogenes contribute to predicting immunotherapy benefits and therapeutic agents in head and neck squamous cell carcinoma. Tan L; Qin Y; Xie R; Xia T; Duan X; Peng L; You R; Liu Y; Zou X; Zhang M; Lin M; Chen M Theranostics; 2022; 12(17):7267-7288. PubMed ID: 36438489 [No Abstract] [Full Text] [Related]
2. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207 [TBL] [Abstract][Full Text] [Related]
3. A Signature of N Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X Front Immunol; 2022; 13():809872. PubMed ID: 35185897 [TBL] [Abstract][Full Text] [Related]
4. Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma. Yue Q; Xu L; Zhang D Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):704-709. PubMed ID: 36416324 [TBL] [Abstract][Full Text] [Related]
5. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. Saleh AD; Cheng H; Martin SE; Si H; Ormanoglu P; Carlson S; Clavijo PE; Yang X; Das R; Cornelius S; Couper J; Chepeha D; Danilova L; Harris TM; Prystowsky MB; Childs GJ; Smith RV; Robertson AG; Jones SJM; Cherniack AD; Kim SS; Rait A; Pirollo KF; Chang EH; Chen Z; Van Waes C Clin Cancer Res; 2019 May; 25(9):2860-2873. PubMed ID: 30723145 [TBL] [Abstract][Full Text] [Related]
6. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. Du K; Zou J; Wang B; Liu C; Khan M; Xie T; Huang X; Shen P; Tian Y; Yuan Y Front Immunol; 2022; 13():857934. PubMed ID: 35844514 [TBL] [Abstract][Full Text] [Related]
7. Application of Machine Learning in Developing a Novelty Five-Pseudogene Signature to Predict Prognosis of Head and Neck Squamous Cell Carcinoma: A New Aspect of "Junk Genes" in Biomedical Practice. Xing L; Zhang X; Guo M; Zhang X; Liu F DNA Cell Biol; 2020 Apr; 39(4):709-723. PubMed ID: 32045271 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma. Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X PeerJ; 2024; 12():e17296. PubMed ID: 38756442 [TBL] [Abstract][Full Text] [Related]
9. Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584 [TBL] [Abstract][Full Text] [Related]
10. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma. Zhou C; Wang S; Shen Z; Shen Y; Li Q; Shen Y; Huang J; Deng H; Ye D; Zhan G; Li J J Clin Lab Anal; 2022 Jan; 36(1):e24113. PubMed ID: 34783061 [TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115 [TBL] [Abstract][Full Text] [Related]
12. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential. Sun X; Fu S; Yuan X; Pu X; Wang R; Wang X; Lu H Cancer Gene Ther; 2023 Sep; 30(9):1209-1214. PubMed ID: 37221404 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive bioinformatics analysis and experimental validation: An anoikis-related gene prognostic model for targeted drug development in head and neck squamous cell carcinoma. Qiu L; Tao A; Sun X; Liu F; Ge X; Li C Oncol Res; 2023; 31(5):715-752. PubMed ID: 37547764 [TBL] [Abstract][Full Text] [Related]
14. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma. Mao L; Pan Z; Chen W; Hu W; Chen X; Dai H BMC Med Genomics; 2023 Mar; 16(1):67. PubMed ID: 36998036 [TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of deregulation microRNA expression in head and neck squamous cell carcinoma. Qi CL; Sheng JF; Huang ML; Zou Y; Wang YP; Wang F; Zeng F; Hua QQ; Chen SM Medicine (Baltimore); 2021 Feb; 100(6):e24618. PubMed ID: 33578572 [TBL] [Abstract][Full Text] [Related]
16. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553 [TBL] [Abstract][Full Text] [Related]
17. miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2. Li X; Zhao S; Fu Y; Zhang P; Zhang Z; Cheng J; Liu L; Jiang H Int J Biol Sci; 2021; 17(15):4327-4339. PubMed ID: 34803501 [TBL] [Abstract][Full Text] [Related]
18. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. Arumugam P; George R; Jayaseelan VP Arch Oral Biol; 2021 Feb; 122():105030. PubMed ID: 33383437 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma. Zhang S; Zhang W; Zhang J Oral Oncol; 2022 Mar; 126():105755. PubMed ID: 35144208 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy. Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q Front Immunol; 2024; 15():1364082. PubMed ID: 38562924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]